Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress GlobeNewswire - Wed Jun 11, 6:00AM CDT

CRVS : 4.34 (+16.35%)
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis GlobeNewswire - Wed Jun 4, 6:00AM CDT

CRVS : 4.34 (+16.35%)
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference GlobeNewswire - Wed May 28, 3:01PM CDT

CRVS : 4.34 (+16.35%)
Corvus: Q1 Earnings Snapshot AP - Thu May 8, 3:39PM CDT

Corvus: Q1 Earnings Snapshot

CRVS : 4.34 (+16.35%)
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results GlobeNewswire - Thu May 8, 3:02PM CDT

CRVS : 4.34 (+16.35%)
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis GlobeNewswire - Thu May 8, 3:01PM CDT

CRVS : 4.34 (+16.35%)
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 GlobeNewswire - Wed Apr 23, 3:08PM CDT

CRVS : 4.34 (+16.35%)
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors GlobeNewswire - Wed Apr 9, 3:01PM CDT

CRVS : 4.34 (+16.35%)
Corvus Pharma Stock Dips On Bigger-Than-Feared Q4 Loss, But Retail’s Faith Grows Stronger Stocktwits - Tue Mar 25, 9:12PM CDT

Research and development expenses in the reported quarter rose by $2 million, primarily due to increased spending on the soquelitinib clinical trial for T-cell lymphoma.

CRVS : 4.34 (+16.35%)
VXF : 191.18 (+1.43%)
IBB : 127.41 (+1.98%)
AVSC : 51.11 (+1.07%)
Corvus: Q4 Earnings Snapshot AP - Tue Mar 25, 3:18PM CDT

Corvus: Q4 Earnings Snapshot

CRVS : 4.34 (+16.35%)

Barchart Exclusives

Teladoc Stock Is a ‘Coiled Spring’ That Could Surge Higher. Should You Buy TDOC Here? Barchart - 1 hour ago
Teladoc stock gains as Citron Research posts a bullish report in its favor. Wall Street remains positive on TDOC shares for the second half of 2025 as well. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot